Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

rPOC 752

X
Drug Profile

rPOC 752

Alternative Names: rPOC-752

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EXUMA Biotech
  • Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical B-cell lymphoma

Most Recent Events

  • 11 Jul 2023 rPOC 752 is available for licensing as of 11 Jul 2023. https://exumabio.com/our-company/partners/ (EXUMA Biotech website, July 2023)
  • 11 Jul 2023 Preclinical trials in B-cell lymphoma in USA (SC) prior to June 2023 (Exuma Biotech pipeline, July 2023)
  • 11 Jan 2021 EXUMA Biotech enters into a strategic collaboration with Moffitt Cancer Center to develop first subcutaneous rapid point-of-care (rPOC) CAR TaNK product for the treatment of B cell malignancies (EXUMA Biotech website, July 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top